Myhep All Tablet

Myhep all is an anti-hepatitis C viral medicine, containing active components known as Sofosbuvir and Velpatasvir available in the strength of 400mg & 100mg respectively.
Velpatasvir is a class of anti-hepatitis C viral drug, called NS5A multiplication complex inhibitors.

This may have combined with other anti-viral agent Sofosbuvir which expels its work by stopping the virus which may causes hepatitis C viral infection from spreading inside the body. Myhep all tablet is not a curable; it is only used to control the spreading of disease. 

Myhepall

BEFORE INITIATION OF THERAPY

Before starting the therapy, patient should be examined by counting hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) for confirmation of HBV infection. The usual recommended dosage of Myhep all tablet is one tablet should be administered as a single dose, by taking with or without food.

IN NEW PATIENTS OR EXPERIENCED PATIENTS WITH OR WITHOUT CIRRHOSIS

The prescribed dosage of Myhep all in this condition is one tablet should be taken as a single dose. 

IN NEW OR ALREADY TREATED PATIENTS WITH DECOMPENSATED CIRRHOSIS

The prescribed dosage of Myhep all in this condition is one tablet to be taken as a single dose by combining with ribavirin.

THE DOSAGE OF RIBAVIRIN

Based on body weight of the patients, the dosage of ribavirin should be recommended. Less than 75kg: 1000mg of ribavirin should be recommended At least 75kg: 1200mg of ribavirin should be recommended Ribavirin must be administered with food. Dosage adjustment should not be recommended in renal and hepatic impairment patients.

OVER DOSAGE

The over dosage of Myhep all tablets; If it occurs manage with supportive measures, and hemodialysis should be recommended for eliminating the components of Myhep all and its metabolite. Sofosbuvir is removed with the coefficient of 53%; Velpatasvir is highly bounds to human plasma protein and it is difficult to eliminate.